ZA200808744B - Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions - Google Patents

Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Info

Publication number
ZA200808744B
ZA200808744B ZA200808744A ZA200808744A ZA200808744B ZA 200808744 B ZA200808744 B ZA 200808744B ZA 200808744 A ZA200808744 A ZA 200808744A ZA 200808744 A ZA200808744 A ZA 200808744A ZA 200808744 B ZA200808744 B ZA 200808744B
Authority
ZA
South Africa
Prior art keywords
rnai
tyrosine kinase
inflammatory conditions
mediated inhibition
spleen tyrosine
Prior art date
Application number
ZA200808744A
Other languages
English (en)
Inventor
John M Yanni
Jon E Chatterton
Daniel A Gamache
Steven T Miller
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA200808744B publication Critical patent/ZA200808744B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200808744A 2006-04-13 2008-10-14 Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions ZA200808744B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79184706P 2006-04-13 2006-04-13

Publications (1)

Publication Number Publication Date
ZA200808744B true ZA200808744B (en) 2009-12-30

Family

ID=38610402

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808744A ZA200808744B (en) 2006-04-13 2008-10-14 Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Country Status (13)

Country Link
US (4) US8048863B2 (de)
EP (3) EP2662446A3 (de)
JP (1) JP2009533475A (de)
KR (1) KR20080110900A (de)
CN (2) CN101443020A (de)
AR (1) AR060448A1 (de)
AU (2) AU2007238027B2 (de)
BR (1) BRPI0709506A2 (de)
CA (1) CA2649138C (de)
MX (2) MX2008013068A (de)
TW (2) TW200808360A (de)
WO (1) WO2007121347A2 (de)
ZA (1) ZA200808744B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001608A (es) * 2007-10-01 2010-03-15 Alcon Res Ltd Suministro mediado por aav auto-complementario de moléculas de arn interferente para tratar o evitar trastornos oculares.
WO2009144230A1 (en) * 2008-05-26 2009-12-03 Universität Zürich Protamine/rna nanoparticles for immunostimulation
EP2299976A4 (de) * 2008-12-22 2014-07-23 Otonomy Inc Ohrsensorzellenmodulierende zusammensetzungen mit gesteuerter freisetzung und verfahren zur behandlung von ohrerkrankungen
EP2865758A1 (de) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA und deren Verwendung in Verfahren und Zusammensetzungen zur Hemmung der Expression des ORAI1-Gens
CN104805085A (zh) * 2014-01-29 2015-07-29 江苏命码生物科技有限公司 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用
US20180036409A1 (en) * 2014-12-29 2018-02-08 Bonac Corporation Composition containing nucleic acid molecule stably
US10888391B2 (en) 2015-05-29 2021-01-12 Ablacon Inc Optical force sensing assembly for an elongated medical device
CA3002786C (en) 2015-10-30 2021-09-07 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-.beta.1 gene
BR102018001541B1 (pt) 2018-01-24 2021-05-11 Universidade Federal Do Rio Grande Do Sul composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
IL122338A0 (en) * 1995-06-07 1998-04-05 Univ Pennsylvania Center For T Methods of inhibiting phagocytosis
CA2526831C (en) * 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
AU2003300504B2 (en) * 2002-10-01 2009-10-01 Epigenomics Ag Method and nucleic acids for the improved treatment of breast cell proliferative disorders
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2298886A3 (de) * 2002-11-22 2011-12-14 Bio-Think Tank Co., Ltd. Verfahren zum Suchen einer Zielbasissequenz einer RNS-Interferenz, Verfahren für die Zuweisung der Basissequenz des Polynukleotid zur Auslösung der RNS-Interferenz, Verfahren zur Herstellung eines doppelstrangigen Polynukleotids, Verfahren zur Hemmung der Genexpression, Basissequenz-Verarbeitungsvorrichtung, Programm zur Ausführung des Basissequenzverarbeitungsverfahrens auf einem Computer, Aufzeichnungsmedium und Basissequenzverarbeitungssystem
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP1692153A4 (de) 2003-07-03 2007-03-21 Univ Pennsylvania Inhibierung der expression von syk-kinase
US20050267059A1 (en) * 2003-11-14 2005-12-01 Diana Beardsley Syk-targeted nucleic acid interference
GB0404209D0 (en) 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
EP1737956A2 (de) 2004-03-01 2007-01-03 Massachusetts Institute of Technology Therapeutika auf rnai-basis gegen allergische rhinitis und asthma
US20090005268A1 (en) * 2005-07-18 2009-01-01 Epigenomics Ag Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers
CA2633035C (en) * 2005-12-15 2016-05-10 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
TW200916117A (en) 2007-08-03 2009-04-16 Alcon Res Ltd RNAi-related inhibition of TNF α signaling pathway for treatment of ocular angiogenesis

Also Published As

Publication number Publication date
WO2007121347A2 (en) 2007-10-25
US20110288157A1 (en) 2011-11-24
AU2013207601B2 (en) 2016-11-17
MX345954B (es) 2017-02-16
KR20080110900A (ko) 2008-12-19
JP2009533475A (ja) 2009-09-17
US20160257963A1 (en) 2016-09-08
AU2007238027A1 (en) 2007-10-25
EP2004240A4 (de) 2010-12-15
US8865671B2 (en) 2014-10-21
US20090324507A1 (en) 2009-12-31
AU2007238027B2 (en) 2013-08-15
US20140357695A1 (en) 2014-12-04
MX2008013068A (es) 2008-12-16
TW200808360A (en) 2008-02-16
AR060448A1 (es) 2008-06-18
BRPI0709506A2 (pt) 2011-07-19
CA2649138A1 (en) 2007-10-25
US9371529B2 (en) 2016-06-21
WO2007121347A3 (en) 2008-12-04
CN101972483A (zh) 2011-02-16
CA2649138C (en) 2018-04-03
CN101443020A (zh) 2009-05-27
EP2662446A3 (de) 2014-04-02
EP2662446A2 (de) 2013-11-13
EP3156486A3 (de) 2017-07-12
EP2004240A2 (de) 2008-12-24
TW201336514A (zh) 2013-09-16
EP3156486A2 (de) 2017-04-19
US8048863B2 (en) 2011-11-01

Similar Documents

Publication Publication Date Title
AU2013207601A1 (en) RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
ZA200808744B (en) Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
HRP20180611T1 (hr) Postupci smanjenja razina bazofila
ZA200809203B (en) Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions
GB2444207B (en) Installation of offshore structures
EP2016423A4 (de) Verfahren zum nachweis von eisenmangel
EP2283269A4 (de) Herstellung und installation von isolierten rohren oder elementen davon
GB0625070D0 (en) Characterization of molecules
EP2040546A4 (de) Tyrosinkinasehemmer
GB0809521D0 (en) Installation of structures in water
IL198774A0 (en) Quinazolines for pdk1 inhibition
ZA200808307B (en) Quinazolines for PDK1 inhibition
IL195803A0 (en) Compositions and methods for sirna inhibition of angiogenesis
EP2083864A4 (de) Antagonisten von pcsk9
EP2083859A4 (de) Pcsk9-antagonisten
EP2083860A4 (de) Pcsk9-antagonisten
EP2106261A4 (de) Pcsk9-antagonisten
EP1978966A4 (de) Tricyclische hemmer von 5-lipoxygenase
ZA200900019B (en) Tyrosine kinase inhibitors
EP1994193A4 (de) Anwendungen von diffusionshärtungsverfahren
EP2217249A4 (de) Hemmung von versican mit sirna und anderen molekülen
PT2222330T (pt) Tratamento de doenças inflamatórias com ace2
ZA200809874B (en) Method of inhibiting c kit kinase
GB2447028B (en) Inhibition of corrosion of structures
GB0608038D0 (en) Fastening of pipes